





# Aumentata incidenza di neoplasie tiroidee e obesità




# Aumentata incidenza di neoplasie tiroidee! = overdiagnosis (microcarcinomi papillari)




Li M *The lancet Diabetes & endocrinology* 2020

# Non solo overdiagnosis di microcarcinomi



Enewold L *Cancer Epidemiol Biomarkers Prev* 2010

# Aumentata incidenza di neoplasie tiroidee? e obesità



# DALYs

## (Disability adjusted life years)

### DALY


Anni di vita persi per malattia  
morte e disabilità

= Anni di vita vissuti  
Con disabilità (YLD) + Anni di  
vita persi (YLL)






# DALYs

## Tumore della tiroide e obesità




INSTITUTE FOR HEALTH METRICS AND EVALUATION

# Fattori di rischio dei Tumori della tiroide




# Obesità: come stimola i Tumori della tiroide







# Stima del rischio di Tumori della tiroide




# Classi di peso e rischio di Tumori della tiroide



Schmid D Obes Rev 2015



# GLP1-agonisti: ↑ rischio di Tumori della tiroide?

~3,7 milioni di T2DM trattati con exenatide, liraglutide, dulaglutide e semaglutide



Bezin J Diabetes Care 2023

# Aumentata incidenza di neoplasie tiroidee e obesità



Screening k tiroide se GLP1-AR?